Phathom Pharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US71722W1071 (PHAT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €97.90M
    Gross margin
    86.9%
    EBIT
    -€230.92M
    EBIT margin
    -235.9%
    Net income
    -€202.45M
    Net margin
    -206.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €278.01M +184.0% -€46.24M -77.2%
    €433.40M +55.9% €66.69M -244.2%
    €609.80M +40.7% €231.03M +246.4%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 9, 2024

    Add to watchlist

    Notifications